IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis
Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jan 9, 2009
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
Atopic dermatitis (AD) is a chronic inflammatory disease of the skin. AD is very frequent, and involves T lymphocytes cells. Measles vaccination, as well as measles vaccine, induces a temporary immunosuppression; furthermore, an improvement of AD has been observed during measles infection.
This trial is aimed at demonstrating that measles vaccine is able to create an immunomodulation and to improve AD symptoms.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adults patients of both sexes, with moderate to severe Atopic Dermatitis (SCORAD (Score for Atopic Dermatitis) ≥ 15).
- Exclusion Criteria:
- • hypersensititvity or contra-indication to a Rouvax® component, Tubertest® component, to egg proteins, immunological deficiency, pregnancy, neomycin
- • allergy,
- • systemic immnosuppressive treatment in the previous 3 months,
- • topic immunosuppressive treatment during the week preceeding the inclusion (gluco-corticoid, or immunosuppressive agent),
- • fever or acute disease (the inclusion must be postpone in such cases).
About Institut National De La Santé Et De La Recherche Médicale, France
The Institut National de la Santé et de la Recherche Médicale (INSERM) is France's key public research organization dedicated to advancing knowledge in health and biomedical sciences. Established to foster innovation and improve public health outcomes, INSERM conducts a wide range of clinical trials and research initiatives aimed at translating scientific discoveries into effective medical treatments and interventions. With a focus on collaboration among researchers, healthcare professionals, and industry partners, INSERM plays a pivotal role in shaping health policies and enhancing the quality of care in France and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pierre Bénite, Lyon, France
Patients applied
Trial Officials
Branka Horvat, MD, PhD
Study Director
Institut National de la Santé Et de la Recherche Médicale, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials